Friday 29 July
Dinutuximab beta as immunotherapy in high-risk neuroblastoma
Meet the experts 2
This talk will provide an overview of the clinical evidence for the use of QARZIBA® in high-risk neuroblastoma, with guidance on dosing, administration, and adverse event management
Session Chair: Dr Martin Campbell
Consultant Oncologist, Clinical Lead Solid Tumours and Neuro-Oncology, Royal Children’s Hospital Melbourne, Australia
Dr Marty Campbell is a Paediatric Oncologist at The Royal Children’s Hospital (RCH) Melbourne. He is the head of the Solid/CNS Tumour Group Program and Medical Director of the Clinical Trials Unit at the Children’s Cancer centre. Dr Campbell is a member of the Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG) and the Children’s Oncology Group (COG). He is the Principal Investigator for COG trials at RCH and is currently the Acting Chair of the Solid Tumour Group for ANZCHOG. Dr Campbell is a fulltime clinician with a main interest in solid tumours, particularly in neuroblastoma, Wilms tumour, rhabdomyosarcoma and retinoblastoma.
Speaker: Dr Aleksandra Wieczorek
Clinician and academic lecturer, University Children’s Hospital, Krakow, Poland
Dr Aleksandra Wieczorek is a pediatrician, pediatric oncologist and hematologist and clinical immunologist. She graduated Jagiellonian University Medical College. After the fellowship in St Anna Kinderspital in Vienna, she works in the University Children’s Hospital, Jagiellonian University Medical College in Krakow as a clinician and academic lecturer. Dr Wieczorek’s main research interest is neuroblastoma and immunotherapy in solid tumors. She is also interested in new drugs development, and University Children’s Hospital in Krakow when she works is the only ITCC center in Poland. Dr Wieczorek is a SIOPEN member, and from 2017-2021 she was a member of the SIOPEN Executive Committee.